Journal of the American Academy of Child & Adolescent Psychiatry
New researchGestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study
Section snippets
Data Sources and Study Population
We used a population-based, prospective cohort study design. All data were collected from national registers linked by the unique personal identification number assigned to all citizens and permanent residents of Finland. In Finland, all children regularly attend child welfare clinics where trained public health nurses or physicians perform medical examinations; this is offered to all and is free of charge. These services are particularly designed to identify psychiatric and neurodevelopmental
Results
Maternal and family characteristics tested as covariates by exposure status are shown in Table 1, tested by offspring outcome diagnosis in Table S1 (available online), and specifically for offspring depression in Table S2 (available online). The distribution of offspring by birth year demonstrates that in the SSRI exposed group, fewer offspring were in the oldest age cohort (1.6%) compared to offspring in the psychiatric disorder, no medication group (2.3%), or the SSRI discontinued group
Principal Findings
Using national register data, we observed increased rates of depression emerging at 12 to 14 years in offspring exposed prenatally to SSRIs. Taking into account maternal underlying psychiatric disorder, SSRI exposure was not associated with an increased risk of ASDs, ADHD, or anxiety. This study, like all studies attempting to answer questions about the long-term effects of in utero exposure to SSRIs, was observational, as it would not be possible to carry out a clinical trial of different
References (29)
- et al.
National trends in antidepressant medication treatment among publicly insured pregnant women
Gen Hosp Psychiatry
(2013) - et al.
Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice
Science
(2004) - et al.
Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice
J Neurosci
(2008) - et al.
Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence
Clin Pharmacol Ther
(2009) - et al.
Placental transfer of SSRI and SNRI antidepressants and effects on the neonate
Pharmacopsychiatry
(2009) - et al.
Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI)
BMC Psychiatry
(2012) - et al.
Offspring of depressed parents: 20 years later
Am J Psychiatry
(2006) - et al.
Specialized service use for psychiatric and neurodevelopmental disorders by age 14 in Finland
Psychiatr Serv
(2014) - et al.
Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism
N Eng J Med
(2013) - et al.
Antidepressant exposure in pregnancy and risk of autism spectrum disorders
Clin Epidemiol
(2013)
Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system
Mol Psychiatry
In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study
BMJ Open
Antidepressant use during pregnancy and childhood autism spectrum disorders
Arch Gen Psychiatry
Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study
BMJ
Cited by (165)
Behavioural outcomes of children exposed to antidepressants and unmedicated depression during pregnancy
2023, Journal of Affective DisordersA simple and sensitive LC-MS/MS method for the quantitation of sertraline and N-desmethylsertraline in human plasma
2023, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesThe impact of antidepressants on human neurodevelopment: Brain organoids as experimental tools
2023, Seminars in Cell and Developmental BiologyCitation Excerpt :Similarly, Kieviet and colleagues reported that, while severe symptoms such as convulsions are rare, 20–77% of infants exposed to SSRIs in utero have sleeping difficulties, tremors, agitation/irritability, and frequent crying [58]. An increased rate of depression diagnoses in early adolescence was also associated with prenatal SSRI exposure [64]. However, unquestionable correlations and causal links between these symptoms and SSRI exposure during development remain to be established [121].
Prenatal Selective Serotonin Reuptake Inhibitor Exposure, Depression, and Brain Morphology in Middle Childhood: Results From the ABCD Study
2023, Biological Psychiatry Global Open Science
This article is discussed in an editorial by Drs. Tim F. Oberlander and Simone N. Vigod on page 351.
Clinical guidance is available at the end of this article.
An interview with the author is available by podcast at www.jaacap.org or by scanning the QR code to the right.
This research was supported by National Institutes of Health grant P50MH090966 (all authors), the Sackler Institute for Developmental Psychobiology of Columbia University (M.W., J.G.), grants from the Sigrid Juselius Foundation, the Foundation for Pediatric Research in Finland, and the Finnish Medical Foundation (D.G.).
Ms. Hinkka-Yli-Salomäki and Drs. McKeague and Wickramaratne served as the statistical experts for this research.
The authors thank Juha-Pekka Virtanen, BSc, for data management, and Jukka Huttunen, Project Coordinator, both of the Department of Child Psychiatry, University of Turku, Turku, Finland, for administrative support.
Disclosure: Dr. Weissman has received funding from the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Sackler Foundation, and the Templeton Foundation; and has received royalties from Oxford University Press, Perseus Press, the American Psychiatric Association Press, and MultiHealth Systems, in the past 3 years. None of these disclosures pose conflicts of interest. Drs. Malm, Brown, Gissler, Gyllenberg, McKeague, Wickramaratne, Artama, Gingrich, Sourander, and Ms. Hinkka-Yli-Salomäki report no biomedical financial interests or potential conflicts of interest.